U.S. restrictions on Chinese biotech could harm patients, argues editorial

Summary

The article argues against U.S. efforts to restrict Chinese biotechnology, framing it as an extension of the tech war that would harm patients. It notes proposed legislation to amend the COINS Act to include Chinese biotech licensing, and calls to disregard Chinese clinical-trial data by the FDA. The core argument is that patients benefit from faster, cheaper treatments regardless of where they are invented.

Source

bskyU.S. restrictions on Chinese biotech could harm patients, argues editorialecon.st